194 related articles for article (PubMed ID: 24918790)
1. Effect of renal impairment on the pharmacokinetics, efficacy, and safety of albiglutide.
Young MA; Wald JA; Matthews JE; Yang F; Reinhardt RR
Postgrad Med; 2014 May; 126(3):35-46. PubMed ID: 24918790
[TBL] [Abstract][Full Text] [Related]
2. Pharmacodynamics, pharmacokinetics, safety, and tolerability of albiglutide, a long-acting glucagon-like peptide-1 mimetic, in patients with type 2 diabetes.
Matthews JE; Stewart MW; De Boever EH; Dobbins RL; Hodge RJ; Walker SE; Holland MC; Bush MA;
J Clin Endocrinol Metab; 2008 Dec; 93(12):4810-7. PubMed ID: 18812476
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of the once-weekly GLP-1 receptor agonist albiglutide versus sitagliptin in patients with type 2 diabetes and renal impairment: a randomized phase III study.
Leiter LA; Carr MC; Stewart M; Jones-Leone A; Scott R; Yang F; Handelsman Y
Diabetes Care; 2014 Oct; 37(10):2723-30. PubMed ID: 25048383
[TBL] [Abstract][Full Text] [Related]
4. Albiglutide efficacy and safety in the Latino/Hispanic subpopulation for the integrated phase III program.
Davidson JA; Jones-Leone A; Wilson TH; Nino A; Forero-Schwanhaeuser S; Reinhardt RR
Postgrad Med; 2017 Nov; 129(8):849-857. PubMed ID: 29083275
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of once-weekly glucagon-like peptide 1 receptor agonist albiglutide (HARMONY 1 trial): 52-week primary endpoint results from a randomized, double-blind, placebo-controlled trial in patients with type 2 diabetes mellitus not controlled on pioglitazone, with or without metformin.
Reusch J; Stewart MW; Perkins CM; Cirkel DT; Ye J; Perry CR; Reinhardt RR; Bode BW
Diabetes Obes Metab; 2014 Dec; 16(12):1257-64. PubMed ID: 25155146
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of once-weekly GLP-1 receptor agonist albiglutide (HARMONY 2): 52 week primary endpoint results from a randomised, placebo-controlled trial in patients with type 2 diabetes mellitus inadequately controlled with diet and exercise.
Nauck MA; Stewart MW; Perkins C; Jones-Leone A; Yang F; Perry C; Reinhardt RR; Rendell M
Diabetologia; 2016 Feb; 59(2):266-74. PubMed ID: 26577795
[TBL] [Abstract][Full Text] [Related]
7. Safety, tolerability, pharmacokinetics and pharmacodynamics of albiglutide, a long-acting GLP-1-receptor agonist, in Japanese subjects with type 2 diabetes mellitus.
Seino Y; Nakajima H; Miyahara H; Kurita T; Bush MA; Yang F; Stewart MW
Curr Med Res Opin; 2009 Dec; 25(12):3049-57. PubMed ID: 19863477
[TBL] [Abstract][Full Text] [Related]
8. Albiglutide, a weekly GLP-1 receptor agonist, improves glycemic parameters in Japanese patients with type 2 diabetes over 1 year when added to single oral antidiabetic drugs.
Okuda I; Wilson TH; Yue L; Nakajima H; Carr MC; Tsuboi M; Nino A; Seino Y
Curr Med Res Opin; 2017 Mar; 33(3):431-438. PubMed ID: 27852119
[TBL] [Abstract][Full Text] [Related]
9. Three-year data from 5 HARMONY phase 3 clinical trials of albiglutide in type 2 diabetes mellitus: Long-term efficacy with or without rescue therapy.
Home PD; Ahrén B; Reusch JEB; Rendell M; Weissman PN; Cirkel DT; Miller D; Ambery P; Carr MC; Nauck MA
Diabetes Res Clin Pract; 2017 Sep; 131():49-60. PubMed ID: 28683300
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of an albiglutide liquid formulation compared with the lyophilized formulation: A 26-week randomized, double-blind, repeat-dose study in patients with type 2 diabetes mellitus.
Shaddinger BC; Soffer J; Vlasakakis G; Shabbout M; Weston C; Nino A
Diabetes Res Clin Pract; 2019 Jun; 152():125-134. PubMed ID: 31004676
[TBL] [Abstract][Full Text] [Related]
11. Clinical Pharmacokinetics and Pharmacodynamics of Albiglutide.
Brønden A; Knop FK; Christensen MB
Clin Pharmacokinet; 2017 Jul; 56(7):719-731. PubMed ID: 28050889
[TBL] [Abstract][Full Text] [Related]
12. HARMONY 3: 104-week randomized, double-blind, placebo- and active-controlled trial assessing the efficacy and safety of albiglutide compared with placebo, sitagliptin, and glimepiride in patients with type 2 diabetes taking metformin.
Ahrén B; Johnson SL; Stewart M; Cirkel DT; Yang F; Perry C; Feinglos MN;
Diabetes Care; 2014 Aug; 37(8):2141-8. PubMed ID: 24898304
[TBL] [Abstract][Full Text] [Related]
13. Albiglutide for the treatment of type 2 diabetes mellitus: An integrated safety analysis of the HARMONY phase 3 trials.
Ahrén B; Carr MC; Murphy K; Perkins C; Rendell M; Mallory J; Wilson T; Johnson S
Diabetes Res Clin Pract; 2017 Apr; 126():230-239. PubMed ID: 28284167
[TBL] [Abstract][Full Text] [Related]
14. Albiglutide: A once-weekly glucagon-like peptide-1 receptor agonist for type 2 diabetes mellitus.
Davis PN; Ndefo UA; Oliver A; Payton E
Am J Health Syst Pharm; 2015 Jul; 72(13):1097-103. PubMed ID: 26092960
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and tolerability of albiglutide versus placebo or pioglitazone over 1 year in people with type 2 diabetes currently taking metformin and glimepiride: HARMONY 5.
Home PD; Shamanna P; Stewart M; Yang F; Miller M; Perry C; Carr MC
Diabetes Obes Metab; 2015 Feb; 17(2):179-87. PubMed ID: 25406730
[TBL] [Abstract][Full Text] [Related]
16. Harmony Outcomes: A randomized, double-blind, placebo-controlled trial of the effect of albiglutide on major cardiovascular events in patients with type 2 diabetes mellitus-Rationale, design, and baseline characteristics.
Green JB; Hernandez AF; D'Agostino RB; Granger CB; Janmohamed S; Jones NP; Leiter LA; Noronha D; Russell R; Sigmon K; Del Prato S; McMurray JJV
Am Heart J; 2018 Sep; 203():30-38. PubMed ID: 30015066
[TBL] [Abstract][Full Text] [Related]
17. Once-weekly albiglutide versus once-daily liraglutide in patients with type 2 diabetes inadequately controlled on oral drugs (HARMONY 7): a randomised, open-label, multicentre, non-inferiority phase 3 study.
Pratley RE; Nauck MA; Barnett AH; Feinglos MN; Ovalle F; Harman-Boehm I; Ye J; Scott R; Johnson S; Stewart M; Rosenstock J;
Lancet Diabetes Endocrinol; 2014 Apr; 2(4):289-297. PubMed ID: 24703047
[TBL] [Abstract][Full Text] [Related]
18. Albiglutide does not impair the counter-regulatory hormone response to hypoglycaemia: a randomized, double-blind, placebo-controlled, stepped glucose clamp study in subjects with type 2 diabetes mellitus.
Hompesch M; Jones-Leone A; Carr MC; Matthews J; Zhi H; Young M; Morrow L; Reinhardt RR
Diabetes Obes Metab; 2015 Jan; 17(1):82-90. PubMed ID: 25263215
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of albiglutide, a once-weekly glucagon-like peptide-1 receptor agonist, in patients with type 2 diabetes: A systematic review and meta-analysis.
Kamrul-Hasan ABM; Dutta D; Nagendra L; Bhattacharya S; Singla R; Kalra S
Medicine (Baltimore); 2024 Jun; 103(25):e38568. PubMed ID: 38905435
[TBL] [Abstract][Full Text] [Related]
20. Potential of albiglutide, a long-acting GLP-1 receptor agonist, in type 2 diabetes: a randomized controlled trial exploring weekly, biweekly, and monthly dosing.
Rosenstock J; Reusch J; Bush M; Yang F; Stewart M;
Diabetes Care; 2009 Oct; 32(10):1880-6. PubMed ID: 19592625
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]